HEHayat Erdem-Yurter

Hayat Erdem-Yurter

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hayat Erdem-Yurter has a total of 76 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Modulating microtubule stability via α-tubulin acetylation partially restores Golgi fragmentation in spinal muscular atrophy

    by Peli̇n Zobaroğlu Özer, Memet Gözüböyük, Özge Çeti̇n, Niko Hensel, Güzi̇n Emecen, Adam Malik, Melissa Bowerman, Peter Claus, Hayat Erdem Yurter, Gamze Bora Akoğlu

    Background/aim: Spinal muscular atrophy (SMA) is a neurodegenerative disease caused by the loss of survival of motor neuron (SMN) protein. SMN deficiency leads to perturbations of the cytoskeleton, including microtubules, which are mainly involved in motilityrelated cellular processes. However, the molecular mechanisms of microtubule dysregulation in SMA remain elusive. Alpha (α)-tubulin is a structural component of microtubules, and its posttranslational modifications affect microtubule dynamics. Here, we aimed to investigate α-tubulin acetylation and related molecular mechanisms in SMA. Materials and methods: Two different SMA mouse models, the Drosophila melanogaster model and patient-derived fibroblasts, were used in the study. Western blot and quantitative microscopic analysis were performed to analyze α-tubulin acetylation and related mechanisms. Results: The acetylation level of α-tubulin was decreased in the Drosophila model and in SMA patient fibroblast cells but not in mouse models. This decrease in acetylation is associated with upregulation of the major tubulin deacetylase, HDAC6, in patient cells compared with healthy controls. Microtubules play a role in the organization of the Golgi apparatus, and we demonstrated that increasing α-tubulin acetylation by pharmacological inhibition of HDAC6 partially restored the fragmented morphology of the Golgi apparatus in SMA. Conclusion: Our findings provide new insight into the molecular basis of SMA, indicating that cellular pathologies, including abnormal Golgi morphology, are associated with microtubule dysregulations caused by altered α-tubulin posttranslational modifications and regulatory proteins. Our findings support that microtubule perturbations are part of SMA pathology.

  • Open Access

    Gene Targeted Therapies for Neurodegenerative Disorders: Strategies and Implications in ALS and SMA

    by Ayse Yesbek Kaymaz, Gamze Bora-Akoğlu, Hayat Erdem Yurter, Christopher Grunseich

    Advances in technology have provided a better understanding of the genetic basis of neurodegenerative disorders and their underlying molecular pathophysiology. However, treating these disorders with conventional strategies is a major challenge. The approval of gene targeted therapy for spinal muscular atrophy (SMA) has laid the foundation for developing highly personalized therapies for other neurodegenerative disorders. As intensive research and efforts to advance gene targeted therapies continue, this review provides an overview of viral and non-viral vectors and delivery methods, as well as treatment strategies, including gene addition, replacement, editing, silencing, and splice modulation. Gene targeted approaches and clinical trials for SMA and amyotrophic lateral sclerosis (ALS) have demonstrated success, and additional studies are in progress. The design of efficient clinical trials which facilitate successful translation into clinical practice is of critical importance. Key considerations include the selection of appropriate disease models, understanding the natural history of the disease, and establishing well-defined outcome measures to assess prognosis of the disease and therapeutic efficacy. Finally, the precision of CRISPR-based gene editing offers the potential for one-time corrective therapies for monogenic disorders like SMA and SOD1-ALS.

  • Open Access

    Gene Targeted Therapies for Neurodegenerative Disorders: Strategies and Implications in ALS and SMA

    by Ayse Yesbek Kaymaz, Gamze Bora-Akoğlu, Hayat Erdem Yurter, Christopher Grunseich

    Advances in technology have provided a better understanding of the genetic basis of neurodegenerative disorders and their underlying molecular pathophysiology. However, treating these disorders with conventional strategies is a major challenge. The approval of gene-targeted therapy for spinal muscular atrophy (SMA) has laid the foundation for developing therapies for other neurodegenerative disorders. Highly personalized gene therapy trials have been reported. As intensive research and efforts to advance gene-targeted therapies continue, this review provides an overview of viral and non-viral vectors and delivery methods, as well as treatment strategies, including gene addition, replacement, editing, silencing, and splice modulation. Gene-targeted approaches and clinical trials for SMA and amyotrophic lateral sclerosis (ALS) have demonstrated success, and additional studies are in progress. The design of efficient clinical trials which facilitate successful translation into clinical practice is of critical importance. Key considerations include the selection of appropriate disease models, understanding the natural history of the disease, and establishing well-defined outcome measures to assess prognosis of the disease and therapeutic efficacy. Finally, the precision of CRISPR-gene editing may facilitate the development of new therapies.

  • Rutin increases alpha‐tubulin acetylation via histone deacetylase 6 inhibition

    by Özge Çetin, Suat Sari, Hayat Erdem‐Yurter, Gamze Bora

    Microtubules are dynamic cytoskeletal filaments composed of alpha‐ (α) and beta (β)‐tubulin proteins. α‐tubulin proteins are posttranslationally acetylated, and loss of acetylation is associated with axonal transport defects, a common alteration contributing to the pathomechanisms of several neurodegenerative diseases. Restoring α‐tubulin acetylation by pharmacological inhibition of HDAC6, a primary α‐tubulin deacetylase, can rescue impaired transport. Therefore, HDAC6 is considered a promising therapeutic target for neurodegenerative diseases, but currently, there is no clinically approved inhibitor for this purpose. In this study, using drug repurposing strategy, we aimed to identify compounds possessing HDAC6 inhibition activity and inducing α‐tubulin acetylation. We systematically analyzed the FDA‐approved library by utilizing virtual screening and consensus scoring approaches. Inhibition activities of promising compounds were tested using in vitro assays. Motor neuron‐like NSC34 cells were treated with the candidate compounds, and α‐tubulin acetylation levels were determined by Western blot. Our results demonstrated that rutin, a natural flavonoid, inhibits cellular HDAC6 activity without inducing any toxicity, and it significantly increases α‐tubulin acetylation level in motor neuron‐like cells.


  • Nörodejeneratif Hastalık Araştırmalarında Drosophila melanogaster Modeli

    by Cem Hazir, Gamze Bora, Hayat Erdem Yurter

    İnsan hastalıklarının Drosophila melanogaster’de modellenmesi sayesinde, patofizyolojilerin araştırılması, yeni genlerin ve genetik düzenleyicilerin tanımlanması, klinik çeşitlilik nedenlerinin açıklanabilmesi, yeni tanı ve tedavi yaklaşımlarının geliştirilmesi, ilaç araştırma çalışmalarının yapılabilmesi gibi birçok alandaki gelişmeler hız kazanmıştır. Bu derlemede D. melaonogaster’in model organizma olarak avantajları ve nörodejeneratif hastalıklarla ilişkili araştırmalarda kullanılmasına ilişkin bilgiler verilmektedir.


  • Open Access

    Investigations of Curcumin and Resveratrol on Neurite Outgrowth: Perspectives on Spinal Muscular Atrophy

    by Gamze Bora-Tatar, Hayat Erdem-Yurter

    Spinal Muscular Atrophy (SMA) is an autosomal recessive neurodegenerative disease with progressive muscle weakness and atrophy. SMA is caused by low levels of the Survival of Motor Neuron (SMN) protein, which also leads to neurite outgrowth defects in neuronal cells. Rescue of the outgrowth defect is thought to be a strategy for SMA treatment. Polyphenolic histone deacetylase (HDAC) inhibitors might be good candidates due to their neuritogenic properties. In the present study, it was investigated whether neurite outgrowth defects could be rescued by curcumin and resveratrol, which are SMN-inducing polyphenols, having HDAC inhibition activity. According to our results, although curcumin and resveratrol failed to restore the neurite outgrowth defects, the SMN protein was found to be necessary for the neurite-promoting activity of curcumin in neuron-like PC12 cells.


  • P3.13 Phenolic compounds and their effect on full length and delta7 SMN2 transcripts

    by D. Dayangac-Erden, G. Bora-Tatar, S. Dalkara, H. Erdem-Yurter

  • Power of inhibition activity screening and 3D molecular modeling approaches in HDAC 8 inhibitor design

    by Gamze Bora Tatar, Tenzi̇le Deni̇z Tokluman, Kemal Yelekçi̇, Hayat Yurter

    In-vitro inhibition activity screening and in-silico 3D molecular modeling approaches are important tools for design and development of specific histone deacetylase (HDAC) inhibitors. The objective of this study was to investigate the consistency between these 2 approaches. The HDAC 8 inhibition activities of 8 randomly selected different carboxylic acid derivatives were screened and in-vitro experimental results were compared with in-silico molecular modeling calculations. This study demonstrated that there is no sole gold standard technique for inhibitor design, and it was concluded that a combination of molecular modeling and activity screening assays will ensure more comprehensive and dependable results.